Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Dose Temozolomide or Temozolomide With Thalidomide in Recurrent Glioblastoma
NCT00521482Phase 2Unknown
- Sponsor
- University of Zurich
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in glioblastoma (GBM) comparing Intensive Dose Temozolomide with Temozolomide plus Thalidomide (2 arms). Primary endpoint: Proportion of patients with progression free survival at 6 months. Status: unknown.
02
Drugs
temozolomidethalidomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00521482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00521482.